Please login to the form below

Not currently logged in
Email:
Password:

Dupixent

This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Sanofi and Regeneron’s Dupixent is currently on track to receive approval for uncontrolled CSU this year. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of the interleukin-4 and interleukin-13 pathways, shown in the

Latest news

More from news
Approximately 39 fully matching, plus 38 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....